The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive ...
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer Multicenter prospective ...
Although 76% respondents reported encountering medical misinformation, that exposure was not significantly associated with clinically significant fear of cancer recurrence or self-reported treatment ...
The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...
This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during ...
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer ...
Polynomial equations have long served as a cornerstone of mathematical analysis, offering a framework to understand functions, curves, and dynamic systems. In recent years, the study of these ...
Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback